Literature DB >> 22876121

Mitochondrial genetic background in Ghanaian patients with primary open-angle glaucoma.

Khaled K Abu-Amero1, Michael A Hauser, Gamal Mohamed, Yutao Liu, Jason Gibson, Ana M Gonzalez, Stephen Akafo, R Rand Allingham.   

Abstract

PURPOSE: Prevalence rates for primary open-angle glaucoma (POAG) are significantly higher in Africans than in European or Asians. It has been reported recently that mitochondrial DNA (mtDNA) lineages of African origin, excluding L2, conferred susceptibility to POAG in Saudi Arabia. This prompted us to test the role of mtDNA haplogroups in the incidence of POAG in the Ghanaian population who has a high frequency of L2 lineages.
METHODS: DNA was extracted from two independent cohorts of clinically diagnosed POAG patients (n=373) and healthy controls (n=451). All patients and controls were from Accra and Tema (the southern region of Ghana). The hypervariable region-I (HVS-I) and coding regions comprising mtDNA haplogroup diagnostic polymorphisms were polymerase chain reaction (PCR) amplified and sequenced in all patients and controls and the haplotypes obtained were assorted into haplogroups and their frequencies compared between cohorts.
RESULTS: No statistically significant differences were found in mtDNA haplogroup frequencies between POAG patients and matched controls in this cohort for the various mtDNA haplogroups tested.
CONCLUSIONS: In this Ghanaian cohort, mtDNA haplogroups do not seem to confer susceptibility to POAG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22876121      PMCID: PMC3413447     

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


Introduction

Primary open-angle Glaucoma (POAG) is the main cause of irreversible blindness worldwide [1]. Heritability estimates evidenced that POAG has a strong genetic component [2]. In fact, linkage analysis, case-control and genome-wide association approaches have related more than 20 nuclear genetic loci to POAG [3]. However, these associations only account for about 5% of POAG cases, reinforcing the idea that POAG is a complex multifactorial disorder result of the interaction of multiple genes and environmental factors [4]. In addition, several epidemiological studies have shown that a positive maternal family history significantly increases the risk of developing POAG than a positive paternal family history [5-7] raising the possibility of an involvement of maternal cytoplasmic factors, as the mitochondria, in the transmission and pathogenesis of POAG. A characteristic of the haploid mitochondrial genome (mtDNA) is its high mutation rate due to which has accumulated several polymorphisms, temporal and geographically structured, reflecting the prehistoric spread of humans from Africa to the rest of the world [8]. These diagnostic polymorphisms have been used to assort related individual mtDNA types (haplotypes) into groups (haplogroups) following a hierarchical nomenclature. Major haplogroups were denoted by uppercase roman letters and successive nested groups by alternating integers and lowercase roman letters [9]. For instance, all mtDNA haplotypes of African origin belong to a macro-haplogroup named “L” that comprises several related haplogroups named L0, L1, L2, L3, each of which was further subdivided into sub-haplogroups as L0a, L0b, L0c, and so on. It has been demonstrated that different haplogroup backgrounds could modify numerous disease predispositions [10]. Recently, it has been reported that African mtDNA haplotypes belonging to L haplogroups, excluding L2, confer susceptibility to POAG in the Saudi Arabian population [11]. Taking into account the fact that prevalence of POAG in Africans and populations of African descent is significantly higher than in Europeans and Asians [12], this report raised the possibility that some mtDNA African haplogroups were, at least in part, responsible for the susceptibility of Africans to POAG. To test this hypothesis, we compared mtDNA Haplogroups frequencies in POAG patients from Ghana with that of ethnicity matching controls.

Methods

Patients and control subjects

We recruited 373 Ghanaian POAG patients (with a mean age of 62±12) who satisfied strict clinical criteria for POAG which includes the following: i) appearance of the disc or retinal nerve fiber layer e.g., thinning or notching of disc rim, progressive changes, nerve fiber layer defect; ii) the presence of characteristic abnormalities in visual field (e.g., arcuate scotoma, nasal step, paracentral scotoma, generalized depression) in the absence of other causes or explanation; iii) age greater than 40 years, and iv) open anterior chamber angles bilaterally on gonioscopy. Exclusion criteria included evidence of secondary glaucoma, e.g., pigmentary dispersion syndrome, pseudoexfoliation, history of steroid use or ocular trauma. All cases had onset of glaucoma after age 40 (adult-onset POAG). Patients were recruited from the glaucoma clinic in Accra after signing an informed consent approved by the institutional review board. A second group (n=451 with a mean age of 53.2±10 years) of healthy Ghanian controls free from glaucoma by examination were recruited. Entry criteria for those subjects were age >40, normal IOP, open angles on gonioscopy, and normal optic nerves on examination.

DNA extraction

Peripheral blood (5 ml) was collected in EDTA tubes from all participating individuals. DNA was extracted using the illustra blood genomicPrep Mini Spin Kit from GE Healthcare (Buckinhamshire, UK), and stored at –20 °C in aliquots until required.

Mitochondrial haplogroup assortment

All samples were polymerase chain reaction (PCR) amplified and sequenced for the mtDNA regulatory region hyper variable segment I (HVS-I) and, when necessary, for coding segments comprising one or more additional diagnostic positions (Table 1). Previously described primers and conditions [13] (Table 2) were used. Each 25 µl PCR reaction contained 2.5 µl of 10× reaction buffer with MgCl2 (Amersham Pharmacia Biotech, Piscataway, NJ), 10 pmol of each primer, 100 pmol/µl each of deoxynucleoside triphophates (deoxyadenosine triphosphate, deoxyguanosine triphosphate, deoxycytidine triphosphate and deoxythymidine triphosphate; Perkin-Elmer Corporation, Foster City, CA) in Tris HCl buffer, 1 unit Taq DNA polymerase (Amersham Pharmacia Biotech) and 50 ng genomic DNA template. The mixture was denatured at 95 °C for 5 min and the PCR reaction was carried out for 35 cycles, in a GeneAmp 9700 PCR system (Perkin-Elmer Corporation), under the following conditions: denaturation at 95 °C for 1 min, annealing at 54 °C for 45 s, extension at 72 °C for 1 min and final extension cycle of 72 °C for 7 min. The PCR products were electrophoresed on a 1% agarose gel and detected with 0.5 µg/ml ethidium bromide to confirm the correct amplicon size. Composite haplotypes were assorted into haplogroups following the most recent mtDNA haplogroup nomenclature [14].
Table 1

Haplogroup distribution in POAG patients and controls.

 
Control (n=451)
Case (n=373)
 
Confidence interval
 
HaplogroupN%N%Odds ratioLower limitUpper limitFisher test p-value
L
0
0
1
0.3
-
-
-
0.45
L0
1
0.2
0
0
-
-
-
1.00
L0a
11
2.4
11
2.9
1.22
0.52
2.84
0.67
L1b
33
7.3
36
9.7
1.35
0.83
2.22
0.26
L1c
31
6.9
23
6.2
0.89
0.51
1.56
0.78
L2
17
3.8
15
4.0
1.07
0.53
2.17
0.86
L2a
147
32.6
118
31.6
0.96
0.71
1.28
0.82
L2b
27
6.0
12
3.2
0.52
0.26
1.05
0.07
L2c
10
2.2
8
2.1
0.97
0.38
2.47
1.00
L2d
3
0.7
0
0
-
-
-
0.26
L2e
3
0.7
1
0.3
0.40
0.04
3.88
0.63
L3
6
1.3
1
0.3
0.20
0.02
1.66
0.14
L3a
1
0.2
3
0.8
3.65
0.38
35.22
0.33
L3b
33
7.3
36
9.7
1.35
0.83
2.22
0.26
L3d
43
9.5
24
6.4
0.65
0.39
1.10
0.12
L3e
70
15.5
62
16.6
1.09
0.75
1.58
0.70
L3f
8
1.8
13
3.5
2.00
0.82
4.88
0.13
L3h
0
0
1
0.3
-
-
-
0.45
L4
2
0.4
2
0.5
1.21
0.17
8.63
1.00
L4b
1
0.2
0
0
-
-
-
1.00
M1
0
0
1
0.3
-
-
-
0.45
U6a40.951.31.520.405.700.74
Table 2

Primers used for mitochondrial haplogrouping.

Primer #Primer sequenceAnnealing temp.Product size
MIT-1-F
CCTCCCTGTACGAAAGGACA
57
614
MIT-1-R
TGAGATTGTTTGGGCTACTGC
 
 
MIT-2-F
CGAGCAGTAGCCCAAACAAT
57
664
MIT-2-R
TTTTGGATTCTCAGGGATGG
 
 
MIT-3-F
CCATCCCTGAGAATCCAAAA
57
653
MIT-3-R
ATTTTGCGTAGCTGGGTCTG
 
 
MIT-4-F
TAAACCAGACCCAGCTACGC
55
661
MIT-4-R
AAAGTGGCTGATTTGCGTTC
 
 
MIT-5-F
TCAACTGAACGCAAATCAGC
60
784
MIT-5-R
TGAAATTGATGGCCCCTAAG
 
 
MIT-6-F
CTTAGGGGCCATCAATTTCA
57
705
MIT-6-R
AAGCCTCCTATGATGGCAAA
 
 
MIT-7-F
GCCATCATAGGAGGCTTCATT
59
702
MIT-7-R
TTTCCTGAGCGTCTGAGATGT
 
 
MIT-8-F
CATCTCAGACGCTCAGGAAA
55
730
MIT-8-R
GGGAGGTAGGTGGTAGTTTGTG
 
 
MIT-9-F
TACTACCGTATGGCCCACCA
60
781
MIT-9-R
AGGCTTGGATTAAGGCGACA
 
 
MIT-10-F
ACTGACTATCCTAGAAATCGCTGT
59
741
MIT-10-R
GCAGATAGTGAGGAAAGTTGAGC
 
 
MIT-11-F
CCACGGACTTCACGTCATTA
59
743
MIT-11-R
GGGAGGATATGAGGTGTGAGC
 
 
MIT-12-F
GCATTTACCATCTCACTTCTAGG
57
751
MIT-12-R
AGTGCGATGAGTAGGGGAAG
 
 
MIT-13-F
AGGCACATACTTCCTATTCTACACC
55
740
MIT-13-R
TGATATTTGATCAGGAGAACGTG
 
 
MIT-14-F
ACTGGGAGAACTCTCTGTGCT
55
740
MIT-14-R
ACGAACAATGCTACAGGGATG
 
 
MIT-15-F
TCCATAATATTCATCCCTGTAGCA
57
741
MIT-15-R
GTGGGTACAGATGTGCAGGA
 
 
MIT-16-F
GTTACAATCGGCATCAACCA
55
740
MIT-16-R
AGCTTTTCTAGTCAGGTTAGGTCTA
 
 
MIT-17-F
CCTCAACCCAAAAAGGCATA
59
745
MIT-17-R
GGAGGTCGATGAATGAGTGG
 
 
MIT-18-F
ACGCAAAATTAACCCCCTAA
59
742
MIT-18-R
GCCTAGGAGGTCTGGTGAGA
 
 
MIT-19-F
CCTAGGCGACCCAGACAAT
59
740
MIT-19-R
GATAGTTGAGGGTTGATTGCTGTA
 
 
MIT-20-F
TGCTTACAAGCAAGTACAGCAAT
57
370
MIT-20-R
TGATGTCTTATTTAAGGGGAACG
 
 
MIT-21-F
GGCTCACATCACCCCATAAA
55
720
MIT-21-R
CATGGGCTACACCTTGACCT
 
 
MIT-22-F
GCAAACCCTGATGAAGGCTA
57
632
MIT-22-R
GGGGTCTTAGCTTTGGCTCT
 
 
MIT-23-F
ACTTTGCAAGGAGAGCCAAA
59
672
MIT-23-R
AGGCGGTGCCTCTAATACTG
 
 
MIT-24-F
TCACCTCTAGCATCACCAGTATT
57
660
MIT-24-R
GGAAGGCGCTTTGTGAAGTA
 
 
HVS-I-F
ACT TCA CAA CAA TCC TAA TCC T
60
1200
HVS-I-R
CGG AGC GAG GAG AGT AGC AC
 
 
HVS-II-F
CAT TTA CCG TAC ATA GCA CA
60
820
HVS-II-RGGG AGG GGG TGA TCT AAA AC  

Data analysis

The frequency of each haplogroup among cases and controls were compared with the Fisher’s exact test, and the risk of having the disease if a subject have a certain haplogroup as compared to not having that specific haplogroup was estimated by computing odds ratio and its 95% confidence interval. Mean age of males was compared with the females mean age by t-test. A p-value less than 0.05 was considered significant. There was no need to adjust the significance level of a statistical test to protect against Type I errors when multiple comparisons were being made because we did not find any significant association between any of the mitochondrial haplogroups and the outcome. All analyses were performed using SPSS v.13 statistical analysis software (SPSS Inc., Chicago, IL).

Results

Our cohort consisted of 373 POAG Ghanaian-patients and 451 controls from Accra and Tema in the south of Ghana. There was a statistical significant difference in age (p=0.0001) between patients (mean age 62±12 years) and controls (mean age 53.2±10 years). Table 1 shows the mitochondrial haplogroup distribution among both groups. The results presented in Table 1, shows that there was no statistically significant difference between patients and controls for all mitochondrial haplogroups tested.

Discussion

A well known risk factor for POAG is African descent. At least in part, it seems correlated with other risk factors more prevalent in Africans than in Europeans as thinner corneas, higher percentage of reported diabetes mellitus, or high blood pressure [15]. In addition, it has been reported that mtDNA African L haplogroups, excluding L2, confer susceptibility to POAG in the Saudi Arabia population [11]. We planned to analyze mtDNA frequencies in an African population with high prevalence of POAG, not directly related to the Saudi population and without important ethnic structuring for mtDNA haplogroup frequencies and POAG prevalence. It seemed us that the Ghana population fulfilled these requisites because it has prevalence of POAG comparable to those in African descent populations of USA, Barbados or St. Lucia [16]; it is located in West Africa, far away of the Arabian peninsula and showed a lack of difference in prevalence among different ethnic groups [16] and a great homogeneity of mtDNA profiles in this and surrounding west African countries across different linguistic communities [17,18]. Consequently, the main aim of this work was to compare the mtDNA haplogroup frequencies between cohorts of POAG patients and their age-matched controls in general. Recently, Fendt et al. [17] performed mtDNA haplogrouping on 191 Ghanaian subjects. Whereas the cohort analyzed in this paper are derived from the Ghanaian coastal cities of Accra and Tema which contain multiple tribal groups, that analyzed by Fendt, et al. [17] were primarily from the Akan tribal group in the northern region of the country. The prevalence of most major mtDNA haplogroups was significantly different from that in our control population. Due to these population differences, an analysis comparing cases and controls in our study was not possible. We compared the mitochondrial haplogroups distribution among POAG patients from Accra and Tema with controls from the same area. The results indicate that there was no statistically significant difference between patients and controls for all mitochondrial haplogroups tested. Thus, at least in this part of Ghana, it seems that mtDNA haplogroups do not play a role for the development of POAG. Accra and Tema are located in the deep south of Ghana at the gulf of Guinea coastline. The sub-Saharan African mtDNA haplroup L2 had similar frequencies in both POAG patients and controls and the little difference in frequency was not statistically significant (p=0.86).
  18 in total

Review 1.  Use of y chromosome and mitochondrial DNA population structure in tracing human migrations.

Authors:  Peter A Underhill; Toomas Kivisild
Journal:  Annu Rev Genet       Date:  2007       Impact factor: 16.830

Review 2.  Genetic bases for glaucoma.

Authors:  Nobuo Fuse
Journal:  Tohoku J Exp Med       Date:  2010-05       Impact factor: 1.848

3.  Global data on visual impairment in the year 2002.

Authors:  Serge Resnikoff; Donatella Pascolini; Daniel Etya'ale; Ivo Kocur; Ramachandra Pararajasegaram; Gopal P Pokharel; Silvio P Mariotti
Journal:  Bull World Health Organ       Date:  2004-12-14       Impact factor: 9.408

4.  Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation.

Authors:  Mannis van Oven; Manfred Kayser
Journal:  Hum Mutat       Date:  2009-02       Impact factor: 4.878

5.  Little genetic differentiation as assessed by uniparental markers in the presence of substantial language variation in peoples of the Cross River region of Nigeria.

Authors:  Krishna R Veeramah; Bruce A Connell; Naser Ansari Pour; Adam Powell; Christopher A Plaster; David Zeitlyn; Nancy R Mendell; Michael E Weale; Neil Bradman; Mark G Thomas
Journal:  BMC Evol Biol       Date:  2010-03-31       Impact factor: 3.260

6.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

7.  The African Descent and Glaucoma Evaluation Study (ADAGES): design and baseline data.

Authors:  Pamela A Sample; Christopher A Girkin; Linda M Zangwill; Sonia Jain; Lyne Racette; Lida M Becerra; Robert N Weinreb; Felipe A Medeiros; M Roy Wilson; Julio De León-Ortega; Celso Tello; Christopher Bowd; Jeffrey M Liebmann
Journal:  Arch Ophthalmol       Date:  2009-09

Review 8.  The genetics of primary open-angle glaucoma: a review.

Authors:  R Rand Allingham; Yutao Liu; Douglas J Rhee
Journal:  Exp Eye Res       Date:  2008-11-14       Impact factor: 3.467

9.  The emerging tree of West Eurasian mtDNAs: a synthesis of control-region sequences and RFLPs.

Authors:  V Macaulay; M Richards; E Hickey; E Vega; F Cruciani; V Guida; R Scozzari; B Bonné-Tamir; B Sykes; A Torroni
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

10.  Mitochondrial DNA lineages of African origin confer susceptibility to primary open-angle glaucoma in Saudi patients.

Authors:  Khaled K Abu-Amero; Ana M González; Essam A Osman; José M Larruga; Vicente M Cabrera; Saleh A Al-Obeidan
Journal:  Mol Vis       Date:  2011-06-03       Impact factor: 2.367

View more
  7 in total

1.  The association of mitochondrial DNA haplogroups with POAG in African Americans.

Authors:  Harini V Gudiseva; Maxwell Pistilli; Rebecca Salowe; Larry N Singh; David W Collins; Brian Cole; Jie He; Sayaka Merriam; Naira Khachataryan; Jeffrey Henderer; Victoria Addis; Qi N Cui; Prithvi S Sankar; Eydie Miller-Ellis; Venkata R M Chavali; Gui-Shuang Ying; Douglas Wallace; Joan M O'Brien
Journal:  Exp Eye Res       Date:  2019-01-15       Impact factor: 3.467

2.  Association of apolipoprotein E-219T>G promoter polymorphism with primary open angle glaucoma in Turkish population.

Authors:  Emel Saglar; Banu Bozkurt; Murat Irkec
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

3.  Mitochondrial Genome Study Identifies Association Between Primary Open-Angle Glaucoma and Variants in MT-CYB, MT-ND4 Genes and Haplogroups.

Authors:  Valeria Lo Faro; Ilja M Nolte; Jacoline B Ten Brink; Harold Snieder; Nomdo M Jansonius; Arthur A Bergen
Journal:  Front Genet       Date:  2021-12-16       Impact factor: 4.599

Review 4.  Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma.

Authors:  Pete A Williams; Jeffrey M Harder; Simon W M John
Journal:  J Glaucoma       Date:  2017-12       Impact factor: 2.503

5.  Epidemiological properties of primary open angle glaucoma in Nigeria.

Authors:  Lawan Abdu
Journal:  J Ophthalmol       Date:  2013-05-26       Impact factor: 1.909

6.  Mitochondrial sequence variation in African-American primary open-angle glaucoma patients.

Authors:  David W Collins; Harini V Gudiseva; Benjamin T Trachtman; Matthew Jerrehian; Thomasine Gorry; William T Merritt; Allison L Rhodes; Prithvi S Sankar; Meredith Regina; Eydie Miller-Ellis; Joan M O'Brien
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

7.  Association of primary open-angle glaucoma with mitochondrial variants and haplogroups common in African Americans.

Authors:  David W Collins; Harini V Gudiseva; Benjamin Trachtman; Anita S Bowman; Anna Sagaser; Prithvi Sankar; Eydie Miller-Ellis; Amanda Lehman; Victoria Addis; Joan M O'Brien
Journal:  Mol Vis       Date:  2016-05-16       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.